Concepedia

Zhijun Kang

ZK

Statistics

Publications

14

Citations

1.6K

H-Index

13

Active since

2004

Affiliations

Pfizer (United States)(Current)

The University of Texas MD Anderson Cancer Center

Beth Israel Deaconess Medical Center

Harvard University

The University of Texas Health Science Center at Houston

Zhijun Kang is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

2004–2021

14

Publications

14

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 903 citations · Full text

, , +4

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó et al. · Cancer Research · 2020 · 101 citations · Full text

Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer’s disease

Christopher J. Helal, Mark A. Sanner, Christopher B. Cooper et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 99 citations · Full text

, , +10

An enolase inhibitor for the targeted treatment of ENO1-deleted cancers

Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi et al. · Nature Metabolism · 2020 · 95 citations · Full text

, , +5

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

Michael Soth, Kang Le, Maria Emilia Di Francesco et al. · Journal of Medicinal Chemistry · 2020 · 88 citations · Full text

Rows per page

1–5 of 14